Bank of Nova Scotia
MDGL icon

Bank of Nova Scotia’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bank of Nova Scotia’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,307
Closed -$317K – 1106
2023
Q1 		$317K Buy
1,307
+1
+0.1% +$272 ﹤0.01% 960
2022
Q4 		$379K Buy
+1,306
New +$128K ﹤0.01% 967

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Bank of Nova Scotia's MDGL Position: Q2 2023 in Review

Bank of Nova Scotia sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 1,307 shares — an estimated $317K sold.

Bank of Nova Scotia first reported a position in MDGL in Q4 2022 and held it in 2 quarters. The position peaked at $379K in Q4 2022. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

  • Bank of Nova Scotia reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Bank of Nova Scotia sold 1,307 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $317K.
  • Bank of Nova Scotia first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Bank of Nova Scotia's Madrigal Pharmaceuticals position peaked at $379K in Q4 2022.
  • 208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Bank of Nova Scotia's 13F filing for Q2 2023, filed 3 Aug 2023.